Changes for page AstraZeneca
Last modified by Wilton Risenhoover on 2022/07/06 01:12
Change comment:
Added comment
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -6,11 +6,13 @@ 6 6 7 7 * AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. 8 8 * The company focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. 9 -* The company also has an active R&D presence in 40 other countries spanning the globe with 10,000 - employees work exclusively in R&D.9 +* The company also has an active R&D presence in 40 other countries spanning the globe with 0,000 - employees work exclusively in R&D. 10 10 * Commercial teams of around 43,400 employees are active in more than 100 countries 11 11 12 + 12 12 [[image:AZN0.png||height="175" width="721"]] 13 13 15 + 14 14 = Company Overview = 15 15 16 16 AstraZeneca (LSE:AZN, NASDAQ:AZN) is a global, science-led biopharmaceutical business and its innovative medicines are used by millions of patients worldwide.{{footnote}}https://www.astrazeneca.com/our-company.html{{/footnote}} ... ... @@ -30,6 +30,7 @@ 30 30 * 40 - active R&D presence in other countries spanning the globe 31 31 * 10,000 - employees work exclusively in R&D 32 32 35 + 33 33 The company's pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. 34 34 35 35 * 175projects in its pipeline ... ... @@ -36,6 +36,7 @@ 36 36 * 17new molecular entities in its late-stage pipeline 37 37 * 1new molecular entity approval 38 38 42 + 39 39 [[image:AZN4.png||alt="AZN2.png"]] 40 40 41 41 ... ... @@ -82,6 +82,7 @@ 82 82 * Building expertise and leadership in the most prevalent and highest mortality rate tumour types 83 83 * Delivering across its global footprint 84 84 89 + 85 85 **key disease areas** 86 86 87 87 The company's focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, the company hope to achieve life-changing benefits for patients. ... ... @@ -260,6 +260,7 @@ 260 260 * Alexion integration progressing well, creating new opportunities in rare diseases 261 261 * Operating Expenses in the quarter reflected the addition of Alexion, as well increased R&D expenses across multiple programs, investment in its COVID-19 medicines, and increased SG&A from pre-launch activities following successful pipeline delivery 262 262 268 + 263 263 **Pascal Soriot, Chief Executive Officer, commented:** 264 264 265 265 AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including its long acting antibody combination showing promise in both prevention and treatment of COVID-19. The addition of Alexion furthers its commitment to bring transformative therapies to patients around the world, and I am proud of its colleagues’ ongoing dedication and focus. ... ... @@ -278,6 +278,7 @@ 278 278 * In the US, Total Revenue increased by 29% to $8,305m and in Europe by 40% (31% at CER) to $5,178m, including pandemic COVID-19 vaccine revenue of $736m 279 279 * Growth in Core EPS13 to $5.05 to $5.40, in line with prior guidance. 280 280 287 + 281 281 Oncology Total Revenue of $9,744m in the year to date; an increase of 19% (16% at CER). Oncology represented 38% of overall Total Revenue (YTD 2020: 43%). 282 282 283 283